Screening intervals for diabetic retinopathy and incidence of visual loss: A systematic review

Diabetic Medicine

Volumn 30, Issue 11, 2013, Pages 1272-1292

  Echouffo Tcheugui, J B ^a   Ali, M K ^a   Roglic, G ^b   Hayward, R A ^c,d   Narayan, K M ^a  

^a EMORY UNIVERSITY   (United States)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COST EFFECTIVENESS ANALYSIS; DIABETIC RETINOPATHY; HUMAN; INCIDENCE; PREVALENCE; SCREENING; SYSTEMATIC REVIEW; VISUAL IMPAIRMENT;

AGE OF ONSET; BLINDNESS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; EARLY DIAGNOSIS; EPIDEMIOLOGIC METHODS; HUMANS; INCIDENCE; MIDDLE AGED; TIME FACTORS; VISION SCREENING;

EID: 84885911796     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/dme.12274     Document Type: Article

References (51)

1. Yau JW, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 2012; 35: 556-564.
2. Wilson JGM, Jungner G. Principles and Practice of Screening for Disease. Geneva: World Health Organization, 1968.
3. Saaddine JB, Honeycutt AA, Narayan KM, Zhang X, Klein R, Boyle JP. Projection of diabetic retinopathy and other major eye diseases among people with diabetes mellitus: USA, 2005-2050. Arch Ophthalmol 2008; 126: 1740-1747.
4. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. IX. Four-year incidence and progression of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 1989; 107: 237-243.
5. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol 1984; 102: 527-532.
6. Diabetes Control and Complications Trial Research Group. Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial. Ophthalmology 1995; 102: 647-661.
7. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
8. Stratton IM, Kohner EM, Aldington SJ, Turner RC, Holman RR, Manley SE et al. UKPDS 50: risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis. Diabetologia 2001; 44: 156-163.
9. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br Med J 1998; 317: 703-713.
10. Klein R, Sharrett AR, Klein BE, Moss SE, Folsom AR, Wong TY et al. The association of atherosclerosis, vascular risk factors, and retinopathy in adults with diabetes: the Atherosclerosis Risk in Communities Study. Ophthalmology 2002; 109: 1225-1234.
11. Hutchinson A, McIntosh A, Peters J, O'Keeffe C, Khunti K, Baker R et al. Effectiveness of screening and monitoring tests for diabetic retinopathy-a systematic review. Diabet Med 2000; 17: 495-506.
12. Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet 2010; 376: 124-136.
13. Ferris FL 3rd, Davis MD, Aiello LM. Treatment of diabetic retinopathy. N Engl J Med 1999; 341: 667-678.
14. American Diabetes Association. Diabetic retinopathy. Diabetes Care 2002; 25: s90-s93.
15. National Screening Committee. The UK NSC policy on Diabetic Retinopathy Screening. National Health Service: Gloucester, 2005.
16. Spurling G, Askew D, Jackson C. Retinopathy-screening recommendations. Aust Fam Physician 2009; 38:780-783.
17. Younis N, Broadbent DM, Vora JP, Harding SP. Incidence of sight-threatening retinopathy in patients with type 2 diabetes in the Liverpool Diabetic Eye Study: a cohort study. Lancet 2003a; 361: 195-200.
18. Vijan S, Hofer TP, Hayward RA. Cost-utility analysis of screening intervals for diabetic retinopathy in patients with type 2 diabetes mellitus. J Am Med Assoc 2000; 283: 889-896.
19. Olafsdottir E, Stefansson E. Biennial eye screening in patients with diabetes without retinopathy: 10-year experience. Br J Ophthalmol 2007; 91: 1599-1601.
20. Leese GP. Should diabetes retinal screening intervals change? Diabet Med 2013; 30: 43-45.
21. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. Br Med J 1996; 313: 275-283.
22. Jones S, Edwards RT. Diabetic retinopathy screening: a systematic review of the economic evidence. Diabet Med 2010; 27: 249-256.
23. Agardh E, Agardh CD, Hansson-Lundblad C. The 5-year incidence of blindness after introducing a screening programme for early detection of treatable diabetic retinopathy. Diabet Med 1993; 10: 555-559.
24. Kristinsson JK, Gudmundsson JR, Stefansson E, Jonasson F, Gislason I, Thorsson AV. Screening for diabetic retinopathy. Initiation and frequency. Acta Ophthalmol Scand 1995; 73: 525-528.
25. Henricsson M, Tyrberg M, Heijl A, Janzon L. Incidence of blindness and visual impairment in diabetic patients participating in an ophthalmological control and screening programme. Acta Ophthalmol Scand 1996; 74: 533-538.
26. Hansson-Lundblad C, Holm K, Agardh CD, Agardh E. A small number of older type 2 diabetic patients end up visually impaired despite regular photographic screening and laser treatment for diabetic retinopathy. Acta Ophthalmol Scand 2002; 80: 310-315.
27. Younis N, Broadbent DM, Harding SP, Vora JP. Incidence of sight-threatening retinopathy in Type 1 diabetes in a systematic screening programme. Diabet Med 2003b; 20: 758-765.
28. Maguire A, Chan A, Cusumano J, Hing S, Craig M, Silink M et al. The case for biennial retinopathy screening in children and adolescents. Diabetes Care 2005; 28: 509-513.
29. Misra A, Bachmann MO, Greenwood RH, Jenkins C, Shaw A, Barakat O et al. Trends in yield and effects of screening intervals during 17 years of a large UK community-based diabetic retinopathy screening programme. Diabet Med 2009; 26: 1040-1047.
30. Soto-Pedre E, Hernaez-Ortega MC, Vazquez JA. Six-year retrospective follow-up study of safe screening intervals for sight-threatening retinopathy in patients with diabetes mellitus. J Diabetes Sci Technol 2009; 3: 812-818.
31. Ling R, Ramsewak V, Taylor D, Jacob J. Longitudinal study of a cohort of people with diabetes screened by the Exeter Diabetic Retinopathy Screening Programme. Eye (Lond) 2002; 16: 140-145.
32. Agardh E, Tababat-Khani P. Adopting 3-year screening intervals for sight-threatening retinal vascular lesions in type 2 diabetic subjects without retinopathy. Diabetes Care 2011; 34: 1318-1319.
33. Jones CD, Greenwood RH, Misra A, Bachmann MO. Incidence and progression of diabetic retinopathy during 17 years of a population-based screening program in England. Diabetes Care 2012; 35: 592-596.
34. Thomas RL, Dunstan F, Luzio SD, Roy Chowdury S, Hale SL, North RV et al. Incidence of diabetic retinopathy in people with type 2 diabetes mellitus attending the Diabetic Retinopathy Screening Service for Wales: retrospective analysis. Br Med J 2012; 344: e874.
35. Davies R, Sullivan P, Canning C. Simulation of diabetic eye disease to compare screening policies. Br J Ophthalmol 1996; 80: 945-950.
36. Tung TH, Chen SJ, Shih HC, Chou P, Li AF, Shyong MP et al. Assessing the natural course of diabetic retinopathy: a population-based study in Kinmen, Taiwan. Ophthalmic Epidemiol 2006; 13: 327-333.
37. Liu WJ, Lee LT, Yen MF, Tung TH, Williams R, Duffy SW et al. Assessing progression and efficacy of treatment for diabetic retinopathy following the proliferative pathway to blindness: implication for diabetic retinopathy screening in Taiwan. Diabet Med 2003; 20: 727-733.
38. Javitt JC, Aiello LP, Chiang Y, Ferris FL 3rd, Canner JK, Greenfield S. Preventive eye care in people with diabetes is cost-saving to the federal government. Implications for healthcare reform. Diabetes Care 1994; 17: 909-917.
39. Davies R, Roderick P, Canning C, Brailsford S. The evaluation of screening policies for diabetic retinopathy using simulation. Diabet Med 2002; 19: 762-770.
40. Brailsford S, Rauner M, Gutjahr W, Zeppelzauer W. Combined discrete-event simulation and ant colony optimisation approach for selecting optimal screening policies for diabetic retinopathy. Comput Manage Sci 2007; 4: 59-83.
41. Dasbach EJ, Fryback DG, Newcomb PA, Klein R, Klein BE. Cost-effectiveness of strategies for detecting diabetic retinopathy. Med Care 1991; 29: 20-39.
42. Rein DB, Wittenborn JS, Zhang X, Allaire BA, Song MS, Klein R et al. The cost-effectiveness of three screening alternatives for people with diabetes with no or early diabetic retinopathy. Health Serv Res 2011; 46: 1534-1561.
43. Tung TH, Shih HC, Chen SJ, Chou P, Liu CM, Liu JH. Economic evaluation of screening for diabetic retinopathy among Chinese type 2 diabetics: a community-based study in Kinmen, Taiwan. J Epidemiol 2008; 18: 225-233.
44. Arun CS, Al-Bermani A, Stannard K, Taylor R. Long-term impact of retinal screening on significant diabetes-related visual impairment in the working age population. Diabet Med 2009; 26: 489-492.
45. Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Ophthalmology 1991; 98: 766-785.
46. The Diabetic Retinopathy Study Research Group. Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS report number 8. Ophthalmology 1981; 88: 583-600.
47. Brailsford SC, Davies R, Canning C, Roderick PJ. Evaluating screening policies for the early detection of retinopathy in patients with non-insulin dependent diabetes. Health Care Manag Sci 1998; 1: 115-124.
48. Kohner EM, Stratton IM, Aldington SJ, Holman RR, Matthews DR. Relationship between the severity of retinopathy and progression to photocoagulation in patients with Type 2 diabetes mellitus in the UKPDS (UKPDS 52). Diabet Med 2001; 18: 178-184.
49. Henricsson M, Sellman A, Tyrberg M, Groop L. Progression to proliferative retinopathy and macular oedema requiring treatment. Assessment of the alternative classification of the Wisconsin Study. Acta Ophthalmol Scand 1999; 77: 218-223.
50. Scottish Intercollegiate Guidelines Network (SIGN). Management of diabetes. A national clinical guideline. In: Brown K, Cant B, Twaddle S eds. National Health Service Quality Improvement Scotland. Edinburgh: Scottish Intercollegiate Guidelines Network, 2010: 97-99.
51. Abhary S, Hewitt AW, Burdon KP, Craig JE. A systematic meta-analysis of genetic association studies for diabetic retinopathy. Diabetes 2009; 58: 2137-2147.